Frequency asked questions (FAQs) posed by young-adult participants at high risk for hepatitis C virus (HCV) infection during screening and educational sessions addressed important gaps in HCV knowledge, a recent study found. From 2016 to 2018, 183 young adults (44.3% women, 85.8% Latino) aged <30 years who inject drugs and reside in Rio Arriba or Doña Ana counties in New Mexico were enrolled. The research team compiled deidentified questions during field enrollments. Researchers found:
- FAQs were reviewed and categorized into 4 major domains, including risk/prevention, screening, treatment, and reinfection.
- FAQs were addressed by a team of medical and public health professionals.
- The FAQs addressed key gaps in HCV knowledge.
- The FAQs also highlighted the importance of risk reduction counseling as well as access to safe and effective HCV treatments for this study population.
Knight LL, Wagner K, Leyva Y, et al. Talking about hepatitis C: FAQs from young adults who inject drugs. [Published online ahead of print September 18, 2018]. Health Promot Pract. doi:10.1177/1524839918799455.
This Week's Must Reads
Must Reads in Hepatitis
Glecaprevir/Pibrentasvir Efficacy & Safety Assessed, J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al
HCV Infection Among Children & Young Persons, J Hepatol; ePub 2018 Nov 26; Modin, et al
HCV Patients with Limited Access to Antiviral Therapy, Dig Liver Dis; ePub 2018 Nov 29; Lens, et al
Progression in the Elimination of HCV Infection, PLoS One; ePub 2018 Dec 4; Juanbeltz, et al
Increased HCV Screening in Veteran Populations, Jt Comm J Qual Patient Saf; ePub 2018 Sep 25; Wray, et al